Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. by Lu, Ching-Hua et al.
Lu, CH; Petzold, A; Topping, J; Allen, K; Macdonald-Wallis, C;
Clarke, J; Pearce, N; Kuhle, J; Giovannoni, G; Fratta, P; Sidle,
K; Fish, M; Orrell, R; Howard, R; Greensmith, L; Malaspina, A
(2015) Plasma neurofilament heavy chain levels and disease progres-
sion in amyotrophic lateral sclerosis: insights from a longitudinal
study. Journal of neurology, neurosurgery, and psychiatry, 86 (5).
pp. 565-73. ISSN 0022-3050 DOI: 10.1136/jnnp-2014-307672
Downloaded from: http://researchonline.lshtm.ac.uk/1829321/
DOI: 10.1136/jnnp-2014-307672
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Supplementary Table 1. Clinimetric used in the study.  
Name Formula and meaning 
Amyotrophic Lateral Sclerosis 
Functional Rating Scale 
Revised score (ALSFRS_R) 
A composite functional outcome measure widely used in clinical 
trials and biomarker studies in ALS ranging from 0 (maximum 
disability) to 48 (normal neurological functioning).   
Symptom  onset The time of the earliest reported symptoms, including muscle 
cramps, fasciculation, weakness and speech changes 
Diagnostic latency The time interval between symptoms onset and the diagnosis, 
expressed in months. 
Disease duration at baseline The time interval from symptoms onset to the baseline sampling, 
expressed in months. 
Progression rate at baseline 
(PRB) 
(48 minus the ALSFRS_R score at baseline)/duration in months 
between symptoms onset and baseline. 
Progression Rate at the last 
visit (PRL) 
The progression rate with reference to the last visit/assessment in 
the study. In this study, patients with PRL>1.0, 0.5-1.0, and <0.5 
are defined as ALS-Fast, ALS-Intermediate and ALS-Slow, 
respectively.   
ALSFRS_R slope ALSFRS_R score at 2
nd
 visit minus ALSFRS_R score at 1
st
 visit / 
time between visits. It is used to define the disease progression 
between two consecutive visits. A negative value indicates 
deterioration in function. 
 
 
